ADGI Adagio Therapeutics, Inc.

Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.

$2.98
As of 05/27/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/06/2021
Outstanding shares:  109,715,173
Average volume:  1,095,148
Market cap:   $287,453,753
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BM8NHS1
Valuation   (See tab for details)
PE ratio:   -4.91
PB ratio:   0.64
PS ratio:   0.00
Return on equity:   -62.13%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy